Novo Nordisk enters into research collaboration with Lumen Bioscience

The research-based collaboration will evaluate Lumen Bioscience's technology platform with the aim of creating oral medicines for obesity and other metabolic diseases.

Photo: Stine Tidsvilde

Novo Nordisk and Lumen Bioscience have entered into a research collaboration, according to a press release from the US company.

According to their agreement, the companies will evaluate Lumen's technology platform and explore new strategies for creating oral biologics for treating obesity and other cardiometabolic diseases.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Latest news

See all jobs